Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M1774 plus cemiplimab in previously treated non-squamous NSCLC
jRCT2031230332Phase 2Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of tuvusertib and cemiplimab in Non-small cell lung cancer (NS-NSCLC) (5 arms), sponsored by Merck KGaA. Started Oct 2023; status: active, not recruiting.
02
Drugs
tuvusertibcemiplimab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT2031230332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230332.